Thrombocytopenia in liver disease
Revision as of 16:38, 22 May 2018 by Benjamintillman (talk | contribs)
Thrombocytopenia in liver disease with planned procedure
Avatrombopag (Doptelet)
| Study | Evidence | Comparator | Efficacy |
|---|---|---|---|
| ADAPT-1 | Phase III | Placebo | Superior RR |
| ADAPT-2 | Phase III | Placebo | Superior RR |
Avatrombopag
- High dose 60 mg/d PO on days 1 to 5 (Patients with platelet count <40 x 109/L)
- Low dose 40 mg/d PO on days 1 to 5 (Patients with platelet count 40 x 109/L - <50 x 109/L)
Procedure days were days 10 to 13.